These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17501694)

  • 1. Clinical immunologic approaches for the treatment of Alzheimer's disease.
    Solomon B
    Expert Opin Investig Drugs; 2007 Jun; 16(6):819-28. PubMed ID: 17501694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease and immunotherapy.
    Solomon B
    Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease: will vaccination work?
    Dodart JC; Bales KR; Paul SM
    Trends Mol Med; 2003 Mar; 9(3):85-7. PubMed ID: 12657428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
    Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
    J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol.
    Spooner ET; Desai RV; Mori C; Leverone JF; Lemere CA
    Vaccine; 2002 Dec; 21(3-4):290-7. PubMed ID: 12450704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.
    Bowers WJ; Mastrangelo MA; Stanley HA; Casey AE; Milo LJ; Federoff HJ
    Neurobiol Aging; 2005 Apr; 26(4):393-407. PubMed ID: 15653168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
    Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
    Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological approaches as therapy for Alzheimer's disease.
    Solomon B
    Expert Opin Biol Ther; 2002 Dec; 2(8):907-17. PubMed ID: 12517269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.